Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial

Rationale: Patients with refractory Mycobacterium avium complex (MAC) lung disease have limited treatment options. In the CONVERT study, amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) increased culture conversion rates versus GBT alone by Month 6. Limited data...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Am Thorac Soc
Main Authors: Winthrop, Kevin L., Flume, Patrick A., Thomson, Rachel, Mange, Kevin C., Yuen, Dayton W., Ciesielska, Monika, Morimoto, Kozo, Ruoss, Stephen J., Codecasa, Luigi R., Yim, Jae-Joon, Marras, Theodore K., van Ingen, Jakko, Wallace, Richard J., Brown-Elliott, Barbara A., Coulter, Chris
Formato: Artigo
Idioma:Inglês
Publicado em: American Thoracic Society 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8328368/
https://ncbi.nlm.nih.gov/pubmed/33326356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/AnnalsATS.202008-925OC
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados